Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07660406

Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CT

Keloids are often described as benign dermal fibroproliferative lesions characterized by increased growth beyond the boundaries of the original wound margin.Fibroblasts are considered to be the key cellular mediators of fibrogenesis in keloid scars. Thus this prospective study is going to investigate whether 68Ga-RGD PET/CT may provide evidence for diagnosis and evaluate the effectiveness of treatment.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Keloid Cicatrix Collagen Diseases Connective Tissue Diseases Fibrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Skin and Connective Tissue Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

About this study

Keloids are often described as benign dermal fibroproliferative lesions characterized by increased growth beyond the boundaries of the original wound margin.Fibroblasts are considered to be the key cellular mediators of fibrogenesis in keloid scars. Thus this prospective study is going to investigate whether 68Ga-RGD PET/CT may provide evidence for diagnosis and evaluate the effectiveness of treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a clinical diagnosis of keloids Able to obtain informed consent

Exclusion criteria

  • Pregnant women, children, patients with allergies to contrast media Patients with claustrophobia

Treatment and study plan

68Ga-RGD

Drug

Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga- FAPI will be used to image lesions of keloid by PET/ CT.

Primary outcomes

  1. Correlation with clinical symptoms, laboratory tests

    Time frame: 1 year

    The clinical assessment of keloids commonly includes the Vancouver Scar Scale for objective scar evaluation, along with laboratory inflammatory markers such as complete blood count (CBC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).

Study contacts

Contact information is provided by the study sponsor or research team.

Jiarou Wang, MD

CONTACT

[email protected]

13628477019

Zhaohui Zhu, MD

CONTACT

[email protected]

13611093752

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2027
First posted
Jun 22, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.